Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene ... Amicus Therapeutics, Inc.February 8, 2021 GMT Initial Data Suggest Early Signs of Disease Stabilization in Children with Fatal Neurologic Disease Plan to Submit IND for Next Clinical Study in 2H2021 PHILADELPHIA, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced positive initial results from its first in-human study of its CLN3 Batten disease gene therapy program, AT-GTX-5...
Source: apnews.com